Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H
Cird Galderma, Sophia Antipolis, Valbonne, France.
Pharm Res. 1993 Dec;10(12):1738-44. doi: 10.1023/a:1018922114398.
In order to improve the therapeutic index of adapalene, a new drug under development for the treatment of acne, site-specific delivery to the hair follicles using 50:50 poly(DL-lactic-co-glycolic acid) microspheres as particulate carriers was investigated in vitro and in vivo. The percutaneous penetration pathway of the microspheres was shown to be dependent on their mean diameter. Thus, after topical application onto hairless rat or human skin, adapalene-loaded microspheres (5-microns diameter) were specifically targeted to the follicular ducts and did not penetrate via the stratum corneum. The in vitro release of adapalene from the microspheres into artificial sebum at 37 degrees C was controlled and faster than the in vivo sebum excretion in humans. Aiming to reduce either the applied dose of drug or the frequency of administration, different formulations of adapalene-loaded microspheres were evaluated in vivo in the rhino mouse model. A dose-related comedolytic activity of topical formulations of adapalene-loaded microspheres was observed in this model. Furthermore, by applying a site-specific drug delivery system (0.1% adapalene) every other day or by administering a 10-fold less concentrated targeted formulation (0.01%) every day, a pharmacological activity equivalent to a daily application of an aqueous gel containing drug crystals (0.1% adapalene) was observed. Since an aqueous gel containing 10% adapalene-loaded microspheres was not irritating in a rabbit skin irritancy test, this formulation was applied onto forearms of human volunteers. Site-specific drug delivery was further evidenced by follicular biopsy. Since an aqueous gel containing 10% adapalene-loaded microspheres was not irritating in a rabbit skin irritancy test, this formulation was applied onto forearms of human volunteers. Site-specific drug delivery was further evidenced by follicular biopsy.(ABSTRACT TRUNCATED AT 250 WORDS)
为提高正在研发的治疗痤疮新药阿达帕林的治疗指数,研究了以50:50聚(DL-乳酸-乙醇酸)微球作为微粒载体向毛囊进行位点特异性给药的体外和体内情况。结果表明,微球的经皮渗透途径取决于其平均直径。因此,在无毛大鼠或人体皮肤局部应用后,载有阿达帕林的微球(直径5微米)可特异性靶向毛囊导管,不会通过角质层渗透。37℃时,阿达帕林从微球向人工皮脂的体外释放得到控制,且比人体的体内皮脂排泄更快。为减少药物的给药剂量或给药频率,在犀牛小鼠模型中对不同配方的载有阿达帕林的微球进行了体内评估。在该模型中观察到载有阿达帕林的微球局部制剂具有剂量相关的抗粉刺活性。此外,通过每隔一天应用一次位点特异性给药系统(0.1%阿达帕林)或每天给予浓度低10倍的靶向制剂(0.01%),观察到其药理活性与每天应用含药物晶体的水凝胶(0.1%阿达帕林)相当。由于含10%载有阿达帕林微球的水凝胶在兔皮肤刺激性试验中无刺激性,该制剂被应用于人类志愿者的前臂。毛囊活检进一步证明了位点特异性给药。由于含10%载有阿达帕林微球的水凝胶在兔皮肤刺激性试验中无刺激性,该制剂被应用于人类志愿者的前臂。毛囊活检进一步证明了位点特异性给药。(摘要截短于250字)